Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis
Evangelos Pavlakis(Philipps University of Marburg), Thorsten Stiewe(Philipps University of Marburg)
Cited by 19
Related Papers
mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability
|Nature Communications|2020|171
Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases
|Nature Communications|2014|46
Phosphorylation Control of p53 DNA-Binding Cooperativity Balances Tumorigenesis and Aging
|Cancer Research|2020|30
Functional diversity of the <i>TP53</i> mutome revealed by saturating CRISPR mutagenesis
|bioRxiv (Cold Spring Harbor Laboratory)|2023|3